Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Intranasal ketamine: Phase II data

In a double-blind Phase II trial in 40 patients undergoing

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE